170902-76-8

Basic information

• Product Name: METHYL D-2-(4-FLUOROPHENYL)GLYCINATE
• Synonyms: Benzeneacetic acid, .alpha.-amino-4-fluoro-, methyl ester, (.alpha.R)-;(R)-Methyl 2-aMino-2-(4-fluorophenyl)acetate;Benzeneacetic acid, α-amino-4-fluoro-, methyl ester, (αR)-;methyl(R)-2-amino-2-(4-fluorophenyl)acetate;methyl (2R)-2-amino-2-(4-fluorophenyl)acetate
• CAS NO: 170902-76-8
• Molecular Formula: C9H10FNO2
• Molecular Weight: 183.18
• Mol File: 170902-76-8.mol

Chemical Properties

• Boiling Point: 241.001°C at 760 mmHg
• Flash Point: 99.554°C
• Appearance: /
• Density: 1.214g/cm³
• Vapor Pressure: 0.037mmHg at 25°C
• Refractive Index: 1.518
• CAS DataBase Reference: METHYL D-2-(4-FLUOROPHENYL)GLYCINATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL D-2-(4-FLUOROPHENYL)GLYCINATE(170902-76-8)
• EPA Substance Registry System: METHYL D-2-(4-FLUOROPHENYL)GLYCINATE(170902-76-8)

Safety Data

• Hazardous Substances Data: 170902-76-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
METHYL D-2-(4-FLUOROPHENYL)GLYCINATE is used as a key intermediate in the synthesis of various drugs for its potential therapeutic properties. It contributes to the development of anti-inflammatory medications and analgesics, helping to alleviate pain and reduce inflammation in patients.
Used in Agrochemical Industry:
METHYL D-2-(4-FLUOROPHENYL)GLYCINATE is used as a vital component in the production of herbicides and insecticides. It aids in controlling unwanted plant growth and managing pest populations, ensuring the protection and productivity of agricultural crops.

InChI:InChI=1/C9H10FNO2/c1-13-9(12)8(11)6-2-4-7(10)5-3-6/h2-5,8H,11H2,1H3/t8-/m1/s1

Upstream product

• 67-56-1 methanol 
• 7292-73-1 (2RS)-N-(p-fluorophenyl)glycine 
• 403-42-9 1-(4-fluorophenyl)ethanone 
• 156276-23-2 methyl (p-fluorobenzoyl)formate 
• 403-32-7 (4-fluorophenyl)glyoxal 
• 42718-13-8 α-amino-4-fluorobenzeneacetic acid methyl ester 
• 19883-57-9 (S)-2-amino-2-(4-fluorophenyl)acetic acid 
• 140-75-0 para-fluorobenzylamine 
• 153903-23-2 (4-fluorobenzyl)carbamic acid tert-butyl ester 
• 93939-74-3 (R)-2-(4-fluorophenyl)glycine 
• 351-95-1 N-(4-fluoro-phenyl)-glycine 
• 196707-32-1 (2R)-2-{[(tert-butoxy)carbonyl]amino}-2-(4-fluorophenyl)acetic acid 
• 196707-30-9 N-(trimethylsilyl)-N-(tert-butyloxycarbonyl)-4-fluorobenzylamine 

Downstream Products

• 170902-74-6 (S)-methyl 2-amino-2-(4-fluorophenyl)acetate 
• 19883-57-9 (S)-2-amino-2-(4-fluorophenyl)acetic acid 
• 1325732-16-8 methyl 4-benzoyl-2-(4-fluorophenyl)-5-(4-nitrophenyl)-2,5-dihydro-1H-pyrrole-2-carboxylate 
• 1325732-18-0 methyl 4-benzoyl-2-(4-fluorophenyl)-5-(4-nitrophenyl)-2,5-dihydro-1H-pyrrole-2-carboxylate 
• 1609081-88-0 rac-methyl [({8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridin-3-yl}-carbonyl)amino](4-fluorophenyl)acetate 
• 1418283-37-0 N-[methoxycarbonyl(4-fluorophenyl)methyl]-2-(2,4-dichlorophenoxy)propanamide 
• 1418283-38-1 N-[carboxy(4-fluorophenyl)methyl]-2-(2,4-dichlorophenoxy)propanamide 
• 1456506-82-3 (S)-4-(4-fluorophenyl)-5,5-dimethyloxazolidin-2-one 
• 1456504-76-9 (S)-4-(4-(4-fluorophenyl)-5,5-dimethyl-2-oxooxazolidin-3-yl)-N-(quinolin-8-yl)benzamide 
• 888028-36-2 (1S)-1-amino-1-(4-fluorophenyl)-2-methylpropan-2-ol 
• 1146361-91-2 2,2,2-trifluoro-N-[(R)-1-(4-fluorophenyl)-2-hydroxy-2-methylpropyl]-acetamide 
• 1146361-93-4 (R)-1-amino-1-(4-fluorophenyl)-2-methylpropan-2-ol 
• 1146361-95-6 (R)-1-(2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-ylamino)-1-(4-fluorophenyl)-2-methylpropan-2-ol 
• 1146361-96-7 (R)-1-(2-chloro-5-oxo-6,7-dihydro-5H-5λ⁴-thieno[3,2-d]pyrimidin-4-ylamino)-1-(4-fluorophenyl)-2-methylpropan-2-ol 

Relevant articles and documents

A Structure?Activity Relationship Study of Novel Hydroxamic Acid Inhibitors around the S1 Subsite of Human Aminopeptidase N

Aminopeptidase N (APN/CD13) is a zinc-dependent ubiquitous transmembrane ectoenzyme that is widely present in different types of cells. APN is one of the most extensively studied metalloaminopeptidases as an anti-cancer target due to its significant role in the regulation of metastasis and angiogenesis. Previously, we identified a potent and selective APN inhibitor, N-(2-(Hydroxyamino)-2-oxo-1-(3′,4′,5′-trifluoro-[1,1′-biphenyl]-4-yl)ethyl)-4-(methylsulfonamido)benzamide (3). Herein, we report the further modifications performed to explore SAR around the S1 subsite of APN and to improve the physicochemical properties. A series of hydroxamic acid analogues were synthesised, and the pharmacological activities were evaluated in vitro. N-(1-(3′-Fluoro-[1,1′-biphenyl]-4-yl)-2-(hydroxyamino)-2-oxoethyl)-4-(methylsulfonamido)benzamide (6 f) was found to display an extremely potent inhibitory activity in the sub-nanomolar range.

A class of 2 - substituted - (S)- (3 - mercapto -2 - methyl propionyl) - glycine derivatives of preparation and use (by machine translation)

The invention provides a 2 - substituted - (S)- (3 - mercapto - 2 - methyl propionyl) - glycine derivatives, shown as formula I: . The present invention also provides 2 - substituted - (S)- (3 - mercapto - 2 - methyl propionyl) - glycine derivatives of th

NOVEL AMINOPEPTIDASE INHIBITORS AND METHODS OF USE

An aminopeptidase inhibitor compound comprising a biaryl, hydroxamic acid based core of formula: wherein X is a 5 or 6-membered ring, and including pharmaceutically acceptable salts and solvates thereof.

Rh-catalyzed asymmetric hydrogenation of racemic aldimines via dynamic kinetic resolution

Catalyzed by a rhodium complex of P-stereogenic diphosphine ligand trichickenfootphos (TCFP), asymmetric hydrogenation of racemic aldimines via dynamic kinetic resolution has been realized for the preparation of chiral arylglycines with good yields and enantioselectivities.

Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions

Malaria remains a global health problem, and though international efforts for treatment and eradication have made some headway, the emergence of drug-resistant parasites threatens this progress. Antimalarial therapeutics acting via novel mechanisms are urgently required. Plasmodium falciparum M1 and M17 are neutral aminopeptidases which are essential for parasite growth and development. Previous work in our group has identified inhibitors capable of dual inhibition of PfA-M1 and PfA-M17, and revealed further regions within the protease S1 pockets that could be exploited in the development of ligands with improved inhibitory activity. Herein, we report the structure-based design and synthesis of novel hydroxamic acid analogues that are capable of potent inhibition of both PfA-M1 and PfA-M17. Furthermore, the developed compounds potently inhibit Pf growth in culture, including the multi-drug resistant strain Dd2. The ongoing development of dual PfA-M1/PfA-M17 inhibitors continues to be an attractive strategy for the design of novel antimalarial therapeutics.

COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS

The present invention relates to new medicament combinations which contain in addition to one or more PDE4-inhibitors (1) at least one EP4 receptor antagonist (2), as well as the use thereof for the treatment of preferably respiratory complaints such as particularly COPD, chronic sinusitis and asthma. The invention relates in particular to those medicament combinations which contain, in addition to one or more, preferably one, PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 have the meanings given in claim 1, at least one EP4 receptor antagonist (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF

Compounds of Formula (I) and Formula (II) are useful inhibitors of tankyrase. Compounds of Formula (I) and Formula (II) have the following structure: where the definitions of the variables are provided herein.

DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which contain, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 have the meanings given in claim 1, at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

Substituted pteridines for the treatment of inflammatory diseases

The invention relates to new pteridines which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula I: (where variables R1, R2, R3, R7, G, J, Q, T, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache, and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.